Shop
Showing 121–150 of 429 results
-
-
-
-
DistributionDong Sung Pharm. Co., Ltd.
-
-
-
-
VentureDongbang Medical
Dongbang Medical has strived to produce high-quality medical devices since its establishment in 1985. They export their unique brands in high-quality oriental medical devices, fillers, bio-medical devices, and cosmetics devices to around 50 countries.
-
-
-
-
-
SMEDXVX
DXVX is a company that has been involved in various activities. They have launched a probiotic for babies in the global market and have also launched two of their own brand antibiotics in the Chinese antibiotic market, which is the world’s largest. They have also been selected for a national R&D project for technology development for the diagnosis of adult diseases.
-
VentureEHL Bio
-
-
-
-
Venture
Ensol Biosciences Inc.
-
-
VentureEutilex
The core technology that the Eutilex employs for drug development is selecting targets that faithfully enhance or suppress human immune responses. A series of immunomodulatory antibody therapeutics have been developed on that principle to treat cancers and autoimmune diseases.
-
VentureExoCoBio
Exosomes are nano-vesicles between 30 and 150 nm, secreted by cells for intercellular signaling. They contain a variety of physiologically active substances and play key roles in important cellular processes.
-
VentureExosome Plus
Exosome Plus was founded in 2018 to drive an extracellular vesicle (EV) revolution, bringing the best EV isolation and characterization platform in the field of regenerative therapy.
-
VentureEXOSTEMTECH
ExoStemTech’s main pipeline is stem cell-derived exosome therapeutics for various indications including osteoarthritis, liver fibrosis, and lung fibrosis. Especially, Cartisome®, the lead asset to treat osteoarthritis, is about to enter a phase 1 clinical trial as of October 2022.
-
DiagnosticsEYEGENE lnc. LTD
EYEGENE Inc. is a clinical-stage biopharmaceutical company developing vaccines and new innovative recombinant protein drugs.
-
VentureFatiAbGen Co., Ltd.
FatiAbGen is a company that focuses on innovating novel immunotoxin antibody assets and regulating stem cell fate with cutting-edge technologies.
-
-
-
-
-
VentureFuture Medicine
Future Medicine is a company that develops new drugs that regulate various in vivo targets involving nucleosides. They are working on creating globally innovative drugs for diseases without treatments. Their core research capabilities include a variety of neurological disease models, in vivo and in vitro efficacy assessment systems, and a system for mechanistic studies.